Methods for the treatment of multiple myeloma

Details Methods for the treatment of multiple myeloma Methods for the treatment of multiple myeloma

2006-04-24

2010-11-02

Bristol, Lynn (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07825088

ABSTRACT:
Methods for treating multiple myeloma with inhibitors of CXCR4 are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.

REFERENCES:
patent: 6825351 (2004-11-01), McEachern et al.
patent: 6835731 (2004-12-01), Bridger et al.
patent: 7238711 (2007-07-01), Grainger et al.
patent: 2005/0154005 (2005-07-01), Bridger et al.
patent: 2005/0277670 (2005-12-01), Zhou et al.
patent: 2004/087068 (2004-10-01), None
Gupta et al. (Immunol. Letters 78:29-34 (2001).
Burger et al. (Blood 94(11):3658-3667 (Dec. 1, 1999).
Shen et al. (Exp. Hematol. 29:1439-1447 (2001).
Dummer Curr. Opin. Investig. Drugs 2(6):844-848 (2001).
BioSpace Beat Dec. 8, 2003).
Hussein (Expert. Opin. Pharmacother. 7(6):767-781 (2006)).
Yeh et al. (Eur. J. Cancer 42:1554-1563 (2006)).
Seaver (1994; Genetic Engineering vol. 14(14):pp. 10 and 21).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Exact Antigen website, “CXCR4 antibody” (pp. 1-3; Nov. 3, 2008).
prosci-inc.com website, “CXCR4 antibody” (pp. 1-2; Nov. 3, 2008).
ebioscience.com website, “anti-human CXCR4” (pp. 1-2, Nov. 3, 2008).
abcam.com website, “CXCR4 antibodies” (p. 1; Nov. 3, 2008).
Sachpatzidiz et al. (J. Biol. Chem. 278(2): 896-907 (2003).
Fujimori et al. (J. Nuc. Med. 31:1191-1198 (1990)).
Beckman et al. (Can. 109:170-179 (2007)).
Thurber et al. (Adv. Drug Deliv. Rev. 60:1421-1434 (2008)).
Rudnick et al. (Can. Biotherp. & Radiopharm. 24: 155-162 (2009)).
Stein (Stein, C.A., Pharmacology and Therapeutics 85: 231-236, 2000).
Stein, C.A., J. Clinical Investigation 108(5): 641-644, 2001).
Caplen, N. J., August, Gene Therapy 11(16): 1241-1248, 2004.
Lopez-Giral et al. (J. Leukocyte Biol. 76:462-471 (Aug. 2004)).
RNDSystems Antibody Reference Guide (CXCR4 antibody, pp. 1-2), (Oct. 10, 2007).
Wikipedia definition for monoclonal antibody (pp. 1-4) (May 14, 2008).
Wikipedia definition for polyclonal antibodiy (pp. 1-4), (May 14, 2008).
Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).
Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)).
clinicaltrials.gov website (list of trials for AMD3100 and myeloma) pp. 1-3 (Oct. 6, 2008).
Devine et al. (J. Clin. Oncol. 22(6):1095-1102 (Mar. 15, 2004)).
Liles et al. (ref. 49 (Blood 102:2728-2730 (2003)).
Finer et al., “kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes”,Blood, 83(1):43-50 (1994).
Hideshima et al., “Novel Therapeutic Approaches for Multiple Myeloma”,Immunological Reviews, 194, (2003),164-176.
Li et al., “The P190, P210, and P230 Forms of theBCR/ABLOncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity”, J. Exp. Med., 189(9):1399-1412 (1999).
Moller et al., “Expression and Function of Chemokine Receptors in Human Multiple Myeloma”,Leukemia, 17. (2003),203-210.
Burger, et al., “Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells”,Blood, 94(11),(1999),3658-3667.
Doench, et al., “siRNAs can function as miRNAs”Genes&Development, 17,(2003),438-442.
Gupta, et al., “Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1x: implications for development of selective CXCR4 antagonists”,Immunology Letters, 78,(2001),29-34.
Shen, et al., “The Chemokine Receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in bone marrow”,Exp. Hematology, 2, (2001),1439-1447.

Affiliated with

Also associated with

Rating

Methods for the treatment of multiple myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the treatment of multiple myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of multiple myeloma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166433